TUSTIN, CA--(Marketwire - November 15, 2010) - Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today the launch of a new version of its Onko-Sure® product website located at www.onko-sure.com.
The patient- and healthcare professional-focused site offers more in-depth product information for the Company's USFDA-approved Onko-Sure® In Vitro Diagnostic (IVD) cancer test, along with an expanded product 'resources' section that offers a technical documents area where users can easily access RPC's white papers, clinical trial data and information, product training presentations and published articles. Restructured product pages also make it more intuitive for the users to access important regulatory, technical and patient use information. The site includes a link to RPC's Investor Video Channel -- a recently launched investor-focused website that features videos communicating RPC's business model, target markets and international distribution, sales and growth strategy; RPC as an investment opportunity; updates and progress on RPC's portfolio of cancer diagnostic products, including its FDA-approved Onko-Sure® cancer test kit; and educational information specifically targeted towards patients, physicians and the healthcare community in general.
According to RPC's Executive Chairman and CEO Douglas MacLellan, "We are extremely thrilled to enhance our Onko-Sure® product website. Our focus was to create a site that not only reflects where we are as company today, but where we are headed in the future. Equally important, we wanted to provide a highly comprehensive and easy-to-use resource that provides patients and healthcare professionals with relevant, high-value information on our Onko-Sure® IVD cancer tests."
RPC's Onko-Sure® IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection and monitoring of the treatment and/or recurrence of various types of cancer. The test enables physicians and healthcare professionals to effectively detect and/or monitor certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure® is cleared by the US FDA for detection during colorectal cancer treatment and/or for recurrence monitoring in colorectal cancer patients and by Health Canada for the detection, treatment and/or recurrence monitoring of lung cancer. For more information visit www.onko-sure.com.
About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring. The company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.
Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati:
